Danish pharma: Danish pharmaceutical company Lundbeck closes its doors in India


Danish pharmaceutical company Lundbeck, which develops drugs for targeted brain diseases including depression, schizophrenia, Alzheimer’s disease, Parkinson’s disease and migraine, leaves India as part of the company’s global strategy .

Bangalore-based $ 2.7 billion Lundbeck company has a sales and marketing team of around 100 people nationwide. Lundbeck had introduced its patented antidepressant drug to India a few years ago.

“Lundbeck has decided to cease operations in India, in line with our strategy. We will continue to serve the Indian market in accordance with local regulatory requirements, but the drugs we offer in India have suitable alternatives. Patients should talk to their doctor. those alternatives if necessary, ”the company said in an email statement to ET.

The company specializes in developing treatments for diseases of the brain and has treated millions of people for over 70 years, according to their website.

Lundbeck is headquartered in Denmark and has operations in over 50 countries around the world. It has production facilities in Denmark, France and Italy, and research centers in Denmark and the United States. The company has employees in more than 50 countries and employs approximately 5,600 people across the value chain.


Comments are closed.